Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENvue Medical filings document the public-company reporting, capital structure, governance, and material agreements of a commercial-stage medical device issuer focused on enteral care and guided feeding tube placement. Recent disclosures include a Form 12b-25 notification related to the timing of the company's annual Form 10-K and the review of financial-statement information.
Material-event filings also cover amendments to employment and equity-award arrangements through ENvue Medical Israel, Ltd., a wholly owned subsidiary, and changes to the rights of holders of the company's Series H Convertible Preferred Stock. These records describe certificate-of-designation amendments, preferred-stock terms, securities-holder rights, and related corporate-governance actions.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of 234,235 shares of ENvue Medical common stock, representing 21.5% of the outstanding class.
The filing shows Bank of America, through BofA Securities, Inc. and Bank of America N.A., has shared voting and dispositive power over these shares and certifies the position is held in the ordinary course of business without the purpose of influencing control. The disclosure notes that the ownership percentage is based on 1,088,192 outstanding shares from a recent ENvue prospectus, which also describes a potential resale of up to 7,962,279 additional shares that could significantly increase outstanding shares and dilute existing holders.
ENvue Medical, Inc. reported changes to leadership compensation and governance. A subsidiary signed a first amendment to the employment agreement with CEO Doron Besser, M.D., confirming an initial grant of 180,000 restricted stock units, equal to 9% of the company’s fully diluted common stock as of his agreement’s effective date.
The amendment also provides quarterly restricted stock unit “gross-up” grants, subject to board approval, to keep Dr. Besser at a 9% equity interest, including a prorated grant if he is terminated without Cause or resigns for Good Reason. Separately, ENvue entered a chairman agreement with David Johnson, who will chair the board as an independent contractor, receive a flat $10,000 monthly fee, and be granted restricted stock units representing 3.5% of fully diluted common stock, plus potential anti-dilution true-up grants for up to two years.
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.
Bank of America Corp, Bank of America NA, and BofA Securities, Inc. jointly reported their initial beneficial ownership in Envue Medical, Inc. as 10% owners. The filing shows indirect ownership of 234,056 shares of common stock, held through Bank of America’s subsidiaries.
The 10% ownership status is based on 1,088,192 outstanding shares disclosed in Envue Medical’s Form 424B3 prospectus, which reports totals as of December 5, 2025. That prospectus covers the potential resale of up to 7,962,279 shares of common stock and notes that issuing additional shares could materially increase shares outstanding and substantially dilute existing stockholders.